Abstract
Echinococcosis still is an important public health challenge in many regions of the world. Up until the 1980s, surgery was considered the only therapeutic option for hydatidosis. However, nowadays, clinicians have effective medical chemotherapy available, which may be utilized singularly or in combination with open surgery or puncture-aspiration-injection-reaspiration (PAIR) method. Benzimidazoles, albendazole and mebendazole, remain the chemotherapeutic cornerstone in the medical management of echinococcosis, acting via cellular inhibition of the tubulin cytoskeletal framework to result in cell death through impaired glucose absorption and adenosine-5′-triphosphate utilization. The isoquinoline praziquantel, by increasing cellular permeability of calcium with consequent muscular paralysis of the worm, both as a protoscolicidal agent and in combination with albendazole, has also been shown to be effective for the medical management of echinococcosis. In patients with inactive or degenerating cysts, there is a role for the “watch and wait” approach. Pharmacovigilance remains an important way of evaluating chemotherapeutic success, adverse effects, and complications. Strategies for the prevention of human hydatidosis will be crucial for reducing central nervous system involvement, particularly in developing countries.
Keywords
- Cystic Hydatid Disease
- Peak Serum Concentration
- Alveolar Hydatid Disease
- Echinococcus Granulosus
- Cystic Echinococcosis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Altinörs N, Bavbek M, Caner HH, Erdogan B. Central nervous system hydatidosis in Turkey: a cooperative study and literature survey analysis of 458 cases. J Neurosurg. 2000;93:1–8.
Ammann RW, Eckert J. Cestodes: Echinococcus. Gastroenterol Clin North Am. 1996;25:655–89.
Bradley M, Horton J. Assessing the risk of benzimidazole therapy during pregnancy. Trans R Soc Trop Med Hyg. 2001;95:72–3.
Bresson-Hadni S, Vuitton DA, Bartholomot B, Heyd B, Godart D, Meyer JP, Hrusovsky S, Becker MC, Mantion G, Lenys D, Miguet JP. A twenty year history of alveolar echinococcosis: analysis of a series of 117 patients from Eastern France. Eur J Gastroenterol Hepatol. 2000;12:327–36.
Brunetti E, Junghanss T. Update on cystic hydatid disease. Curr Opin Infect Dis. 2009;22:497–502.
Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114:1–16.
Budke CM, Deplazes P, Torgerson PR. Global socioeconomic impact of cystic echinococcosis. Emerg Infect Dis. 2006;12:296–303.
Casado N, Pérez-Serrano J, Denegri G, Rodríguez-Caabeiro F. Development of a chemotherapeutic model for the in vitro screening of drugs against Echinococcus granulosus cysts: the effects of albendazole- albendazole sulfoxide combination. Int J Parasitol. 1996;26:59–65.
Ceballos L, Elissondo C, Sánchez Bruni S, Denegri G, Lanusse C, Alvarez L. Comparative performance of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. Antimicrob Agents Chemother. 2011;55:5861–7.
Cobo F, Yarnoz C, Sesma B, Fraile P, Aizcorbe M, Trujillo R, Diaz-de-Liaño A, Ciga MA. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatidosis caused by Echinococcus granulosus. Trop Med Int Health. 1998;3:462–6.
Davis A, Pawlowski ZS, Dixon H. Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis. Bull World Health Organ. 1986;64:383–8.
Davis A, Dixon H, Pawlowski ZS. Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2). Bull World Health Organ. 1989;67:503–8.
de Silva N, Guyatt H, Bundy D. Anthelmintics. A comparative review of their clinical pharmacology. Drugs. 1997;53:769–88.
Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Pin Infect Dis. 2008;21:659–67.
El-On J. Benzimidazole treatment for cystic echinococcosis. Acta Trop. 2003;85:243–52.
Falagas ME, Bliziotis IA. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials. Am J Med Sci. 2007;334:171–9.
Fierlafijn E. Mebendazole in enterobiasis. JAMA. 1971;218:1051.
Friedman PA, Platzer EG. Interaction of anthelmintic benzimidazoles with Ascaris suum embryonic tubulin. Biochem Biophys Acta. 1980;630:271–8.
Gottschall PE. Infectious disease, interleukin-1 and central nervous system. J Fla Med Assoc. 1993;80:127–9.
Gottschall DW, Theodorides VJ, Wang R. The metabolism of benzimidazole anthelmintics. Parasitol Today. 1990;6:115–24.
Hemphill A, Müller J. Alveolar and cystic echinococcosis: towards novel chemotherapeutic treatment options. J Helminthol. 2009;83:99–111.
Horton RJ. Chemotherapy of Echinococcus infections in man with albendazole. Trans R Soc Trop Med. 1989;83:97–102.
Junghanss T, da Silva AM, Horton J, Chiodini PL, Brunetti E. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg. 2008;79:301–11.
Kalaitzoglou I, Drevelengas A, Petridis A, Palladas P. Albendazole treatment of cerebral hydatid disease: evaluation of results with CT and MRI. Neuroradiology. 1998;40:36–9.
Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanisms of drug resistance to benzimidazoles. Int J Parasitol. 1988;18:885–936.
Liu LX, Weller PF. Antiparasitic drugs. N Eng J Med. 1996;334:1178–84.
Luchi S, Vincenti A, Messina F, Parenti M, Scasso A, Campatelli A. Albendazole treatment of human hydatid tissue. Scand J Infect Dis. 1997;29:165–7.
McManus DP, Zhang W, Li J, Bartley PB. Echinococcosis. Lancet. 2003;362:1295–304.
Mohamed AE, Yasawy MI, Karawi MA. Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology. 1998;45:1690–4.
Morris L. Pre-operative albendazole therapy for hydatid cysts. Br J Surg. 1987;74:805–6.
Ntusi NBA, Horsfall C. Severe disseminated hydatid disease successfully treated medically with prolonged administration of albendazole. Q J Med. 2008;101:745–6.
Saimot AG, Meulemans A, Cremieux AC, Giovanangeli MD, Hay JM, Delaitre B, Coulaud JP. Albendazole as a potential treatment for human hydatidosis. Lancet. 1983;2:652–6.
Schantz PM, van den Bossche H, Eckert J. Chemotherapy for larval Echinococcus in animals and humans: report of a workshop. Z Parasitenkd. 1982;67:5–26.
Sheth UK. Mechanisms of anthelmintic action. Prog Drug Res. 1975;19:147–57.
Stojkovic M, Zwahlen M, Teggi A, Vutova K, Cretu CM, Virdone R, Nicolaidou P, Cobanoglu N, Junghanss T. Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. PLoS Negl Trop Dis. 2009;3:e524.
Teggi A, Lastilla MG, De Rosa F. Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Agents Chemother. 1993;37:1679–84.
Todorov T, Mechkov G, Vutova K, Georgiev P, Lazarova I, Tonchev Z, Nedelkov G. Factors influencing the response to chemotherapy in human cystic echinococcosis. Bull World Health Organ. 1992a;70:347–58.
Todorov T, Vutova K, Mechkov G, Georgiev P, Petkov D, Tonchev Z, Nedelkov G. Chemotherapy of human cystic echinococcosis: comparative efficacy of mebendazole and albendazole. Ann Trop Med Parasitol. 1992b;86:59–66.
Turgut M. Hydatid disease of the spine: a survey from Turkey. Infection. 1997;25:221–6.
Turgut M. Intracranial hydatidosis in Turkey: its clinical presentation, diagnostic studies, surgical management, and outcome. A review of 276 cases. Neurosurg Rev. 2001;24:200–8.
Wen H, New RR, Craig PS. Diagnosis and treatment of human hydatidosis. Br J Clin Pharmacol. 1993;35:565–74.
WHO Informal Working Group on Echinococcosis. Guidelines for the treatment of cystic and alveolar echinococcosis in humans. Bull World Health Organ. 1996;74:231–42.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dlamini, S.K., Ntusi, N.B.A. (2014). Chemotherapy for Central Nervous System Hydatidosis. In: Turgut, M. (eds) Hydatidosis of the Central Nervous System: Diagnosis and Treatment. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54359-3_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-54359-3_16
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54358-6
Online ISBN: 978-3-642-54359-3
eBook Packages: MedicineMedicine (R0)